Japan’s Takeda Pharmaceutical to Develop a Vaccine for Zika Virus

Japan’s Takeda Pharmaceutical to Develop a Vaccine for Zika Virus

Japan’s Takeda Pharmaceutical to Develop a Vaccine for Zika Virus


Takeda Pharmaceutical Co. won US government funding to develop a vaccine for the Zika virus, a mosquito-borne pathogen that’s spreading rapidly through the Americas.

The Osaka, Japan-based company was awarded a contract for as much as $312-M from the US Health and Human Services Department (HHS), according to a statement Thursday.

The drugmaker will receive $19.8-M to cover the development through initial trials, and potentially more during later phases. Takeda will start human trials in the second half of next year, Rajeev Venkayya, the company’s head of global vaccines, said.

There are no drugs or vaccines available yet to fight the virus, which is dangerous to women because it can cause brain damage in babies and was linked to some cases of neurological disorders in adults.

The National Institute of Allergy and Infectious Diseases, an agency of HHS, started 1 of the 1st human trials for a Zika vaccine in early August.

Companies from French pharmaceutical giant Sanofi to Pennsylvania-based Inovio Pharmaceuticals Inc. also are working toward a vaccine to combat the virus.

Takeda will harness its work against dengue, a virus from the same family, to develop a vaccine against Zika. The company also is developing programs for infectious diseases such as norovirus and polio.

Symbol Last Trade Date Change Open High Low Volume
OTCMKT:TKPYY 22.865 2 September 2016 0.18 22.95 22.95 22.79 4,987
HeffX-LTN Analysis for TKPYY: Overall Short Intermediate Long
Bullish (0.27) Neutral (0.07) Bullish (0.35) Bullish (0.39)

Have a terrific Labor Day Weekend

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :